Stephen D. Hall

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

Peter Kuehl, Jiong Zhang, Yvonne Lin et al. · Nature Genetics · 2001 · 2.2K citations

Life Sciences, Genetics, Molecular Biology +17

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 594 citations

Medicine, Pharmacokinetics, Pharmacology +17

Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Samir K. Gupta, Joseph A. Eustace, Jonathan Winston et al. · Clinical Infectious Diseases · 2005 · 585 citations · Full text

Medicine, Infectious Diseases, Nephrology +12

Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7

J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell et al. · Drug Metabolism and Disposition · 2002 · 468 citations

Medicine, Biochemistry, Pharmacology +17

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

Naga Chalasani, Hisham Aljadhey, Joe Kesterson et al. · Gastroenterology · 2004 · 441 citations

Medicine, Internal Medicine, Pharmacotherapy +15